Salvatore Petta

List of Publications by Citations

254 papers	10,355 citations	55 h-index	94 g-index
317 ext. papers	13,937 ext. citations	5 avg, IF	6.18 L-index

#	Paper	IF	Citations
254	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *Journal of Hepatology*, **2018**, 69, 896-904	13.4	550
253	Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology*, **2012**, 143, 1253-1260.e4	13.3	471
252	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. *Gastroenterology*, **2016**, 150, 1219-1230.e6	13.3	347
251	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. *Hepatology*, **2010**, 51, 1158-67	11.2	318
250	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology*, **2015**, 61, 506-14	11.2	311
249	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. *American Journal of Gastroenterology*, **2017**, 112, 740-751	0.7	273
248	Statin use and non-alcoholic steatohepatitis in at risk individuals. *Journal of Hepatology*, **2015**, 63, 705-12	13.4	227
247	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. *Gastroenterology*, **2018**, 155, 411-421.e4	13.3	201
246	Non-alcoholic fatty liver disease pathogenesis: the present and the future. *Digestive and Liver Disease*, **2009**, 41, 615-25	3.3	190
245	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. *Hepatology*, **2016**, 63, 2032-43	11.2	183
244	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. *Transplantation*, **2019**, 103, 22-27	1.8	181
243	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. *Digestive and Liver Disease*, **2017**, 49, 471-483	3.3	179
242	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. *Gastroenterology*, **2016**, 150, 145-155.e4; quiz e15-6	13.3	156
241	Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. *American Journal of Gastroenterology*, **2008**, 103, 1136-44	0.7	149
240	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. *American Journal of Gastroenterology*, **2011**, 106, 2112-20	0.7	148
239	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. *Journal of Internal Medicine*, **2018**, 283, 356-370	10.8	140
238	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. *Hepatology*, **2017**, 65, 1145-1155	11.2	135

237	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Scientific Reports*, **2017**, 7, 4492	4.9	131
236	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. *Hepatology*, **2015**, 62, 1101-10	11.2	131
235	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. *Journal of Hepatology*, **2015**, 62, 928-33	13.4	115
234	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. *Journal of Hepatology*, **2020**, 73, 505-515	13.4	113
233	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 510-518	6.1	111
232	Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. *Hepatology*, **2012**, 55, 1317-23	11.2	105
231	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. *Alimentary Pharmacology and Therapeutics* , **2017**, 46, 688-695	6.1	104
230	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 1350-60	6.1	104
229	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. *Hepatology*, **2020**, 71, 1213-1227	12.2	104
228	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *Journal of Hepatology*, **2021**, 75, 659-689	13.4	102
227	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 757-66	6.1	95
226	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. *Liver International*, **2015**, 35, 1566-73	7.9	94
225	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 617-627	6.1	94
224	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. *Hepatology*, **2012**, 56, 850-60	11.2	91
223	Pathophysiology of Non Alcoholic Fatty Liver Disease. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	88
222	Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. *Gastroenterology*, **2011**, 140, 818-29	13.3	85
221	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1604-1611.e1	6.9	83
220	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. *PLoS ONE*, **2014**, 9, e87523	3.7	83

219	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. *Journal of Hepatology*, **2017**, 67, 577-584	13.4	80
218	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *Journal of Hepatology*, **2019**, 71, 265-273	13.4	80
217	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. *Journal of Hepatology*, **2016**, 64, 682-90	13.4	79
216	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. *Hepatology*, **2013**, 57, 1046-54	11.2	78
215	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. *Hepatology*, **2010**, 52, 1543-52	11.2	76
214	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. *Journal of Hepatology*, **2018**, 69, 878-885	13.4	75
213	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 238-47	6.1	74
212	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2012**, 56, 1356-62	13.4	72
211	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. *Hepatology*, **2016**, 63, 787-98	11.2	70
210	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. *Journal of Hepatology*, **2018**, 69, 18-24	13.4	68
209	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. *Hepatology*, **2014**, 59, 1692-705	11.2	64
208	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. *Journal of Hepatology*, **2017**, 67, 65-71	13.4	63
207	Cardiovascular diseases and HCV infection: a simple association or more?. *Gut*, **2014**, 63, 369-75	19.2	60
206	Interferon lambda 4 rs368234815 TT>□ variant is associated with liver damage in patients with nonalcoholic fatty liver disease. *Hepatology*, **2017**, 66, 1885-1893	11.2	59
205	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. *World Journal of Gastroenterology*, **2015**, 21, 11088-111	5.6	59
204	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. *Alimentary Pharmacology and Therapeutics*, **2007**, 25, 1181-91	6.1	59
203	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 160-168	6.1	58
202	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. *Liver International*, **2011**, 31, 507-15	7.9	58

201	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. *Journal of Hepatology*, **2014**, 61, 523-9	13.4	57
200	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. *Hepatology*, **2009**, 49, 195-203	11.2	56
199	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 935-944.e3	6.9	55
198	Hepatitis C and diabetes: the inevitable coincidence?. *Expert Review of Anti-Infective Therapy*, **2009**, 7, 293-308	5.5	54
197	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. *Liver International*, **2017**, 37, 1157-1166	7.9	53
196	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. *Journal of Hepatology*, **2013**, 58, 771-7	13.4	52
195	Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. *Current Pharmaceutical Design*, **2010**, 16, 741-52	3.3	52
194	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. *Hepatology*, **2017**, 65, 1840-1850	11.2	51
193	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. *Science Translational Medicine*, **2020**, 12,	17.5	51
192	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *Journal of Hepatology*, **2021**, 74, 775-782	13.4	50
191	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. *Hepatology*, **2008**, 48, 28-37	11.2	49
190	Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E304-8	5.6	48
189	Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?. *American Journal of Gastroenterology*, **2005**, 100, 2472-7	0.7	48
188	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. *PLoS ONE*, **2013**, 8, e74089	3.7	47
187	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. *JHEP Reports*, **2019**, 1, 188-198	10.3	46
186	Reproductive status is associated with the severity of fibrosis in women with hepatitis C. *PLoS ONE*, **2012**, 7, e44624	3.7	46
185	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 216-225.e5	6.9	46
184	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. *PLoS ONE*, **2016**, 11, e0163069	3.7	45

183	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. *Scientific Reports*, **2019**, 9, 3682	4.9	42
182	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2310-2319.e6	6.9	42
181	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. *DMM Disease Models and Mechanisms*, **2015**, 8, 1037-46	4.1	42
180	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. *Digestive and Liver Disease*, **2016**, 48, 333-42	3.3	42
179	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. *Journal of Viral Hepatitis*, **2013**, 20, 486-93	3.4	42
178	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. *Liver International*, **2018**, 38, 2060-2068	7.9	39
177	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. *PLoS ONE*, **2017**, 12, e0186136	3.7	38
176	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. *Liver International*, **2019**, 39, 1742-1754	7.9	37
175	Recurrence of hepatocellular carcinoma after liver transplantation: an update. *Future Oncology*, **2015**, 11, 2923-36	3.6	37
174	Advancing the global public health agenda for NAFLD: a consensus statement. *Nature Reviews Gastroenterology and Hepatology*, **2021**,	24.2	37
173	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. *Atherosclerosis*, **2020**, 296, 40-47	3.1	36
172	The UCP2 -866□G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. *Liver International*, **2015**, 35, 1574-80	7.9	35
171	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. *Journal of Hepatology*, **2013**, 59, 658-66	13.4	34
170	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*, **2021**,	19.2	31
169	Range of Normal Liver Stiffness and Factors Associated With□Increased Stiffness Measurements in Apparently Healthy□Individuals. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 54-64.e1	6.9	31
168	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2660-2669	5.6	30
167	Is global elimination of HCV realistic?. *Liver International*, **2018**, 38 Suppl 1, 40-46	7.9	30
166	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. *Hepatology Communications*, **2018**, 2, 666-675	6	30

165	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. *Cancer Medicine*, **2017**, 6, 1930-1940	4.8	29
164	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. *Journal of Hepatology*, **2013**, 59, 1169-76	13.4	28
163	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. *Antiviral Therapy*, **2012**, 17, 823-31	1.6	28
162	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. *PLoS ONE*, **2017**, 12, e0185728	3.7	28
161	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. *Contemporary Clinical Trials*, **2020**, 98, 106175	2.3	28
160	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2408-2416	6.7	28
159	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. *Journal of Lipid Research*, **2019**, 60, 1144-1153	6.3	27
158	Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 311-7.e1	6.9	27
157	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. *Hepatology*, **2020**, 71, 1953-1966	11.2	27
156	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. *American Journal of Gastroenterology*, **2019**, 114, 916-928	0.7	27
155	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. *Gut*, **2021**,	19.2	27
154	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. *Liver International*, **2017**, 37, 1389-1396	7.9	26
153	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. *Pharmaceuticals*, **2018**, 11,	5.2	26
152	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. *Medicine (United States)*, **2016**, 95, e3446	1.8	25
151	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. *Journal of Hepatology*, **2018**, 69, 1155-1163	13.4	25
150	Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. *PLoS ONE*, **2015**, 10, e0142210	3.7	24
149	Serum Eglutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. *PLoS ONE*, **2012**, 7, e51165	3.7	24
148	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. *Digestive and Liver Disease*, **2011**, 43, 404-10	3.3	24

147	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. *Liver International*, **2019**, 39, 1325-1334	7.9	23
146	Hepatitis C virus and cardiovascular: A review. *Journal of Advanced Research*, **2017**, 8, 161-168	13	23
145	Current and future HCV therapy: do we still need other anti-HCV drugs?. *Liver International*, **2015**, 35 Suppl 1, 4-10	7.9	23
144	Metabolic factors and chronic hepatitis C: a complex interplay. *BioMed Research International*, **2013**, 2013, 564645	3	23
143	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. *Gastroenterology*, **2021**, 160, 1634-1646.e7	13.3	23
142	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	23
141	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. *Cardiovascular Diabetology*, **2018**, 17, 28	8.7	22
140	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. *Digestive and Liver Disease*, **2020**, 52, 937-941	3.3	22
139	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. *Journal of Clinical Endocrinology and Metabolism* , **2015**, 100, 193-200	5.6	21
138	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 806-815.e5	6.9	21
137	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2021**, 75, 786-794	13.4	21
136	NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. *PLoS ONE*, **2013**, 8, e68364	3.7	20
135	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 603-13	6.1	20
134	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. *Liver International*, **2020**, 40, 1545-1555	7.9	19
133	How to optimize HCV therapy in genotype 1 patients: predictors of response. *Liver International*, **2013**, 33 Suppl 1, 23-9	7.9	19
132	The cheating liver: imaging of focal steatosis and fatty sparing. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 671-8	4.2	19
131	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, **2021**, 75, 770-785	13.4	19
130	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. *Antiviral Therapy*, **2009**, 14, 631-639	1.6	18

129	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. *Journal of Viral Hepatitis*, **2011**, 18, e372-80	3.4	17
128	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 2345-2353	4.5	17
127	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 939-48	6.1	16
126	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. *Liver International*, **2018**, 38, 715-723	7.9	15
125	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. *Liver International*, **2012**, 32, 1443-50	7.9	15
124	Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. *Journal of Viral Hepatitis*, **2009**, 16, 397-405	3.4	15
123	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. *Journal of Viral Hepatitis*, **2008**, 15, 523-30	3.4	15
122	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. *Digestive and Liver Disease*, **2017**, 49, 731-741	3.3	14
121	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. *Digestive and Liver Disease*, **2014**, 46, 936-42	3.3	14
120	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. *Liver International*, **2016**, 36, 1765-1773	7.9	14
119	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 427-434	18.8	13
118	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. *Analytical Cellular Pathology*, **2015**, 2015, 431750	3.4	13
117	From current status to optimization of HCV treatment: Recommendations from an expert panel. *Digestive and Liver Disease*, **2016**, 48, 995-1005	3.3	12
116	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 739-50	5.1	12
115	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 740-749	6.1	12
114	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. *International Journal of Environmental Research and Public Health*, **2019**, 16,	4.6	12
113	Liver and Statins: A Critical Appraisal of the Evidence. *Current Medicinal Chemistry*, **2018**, 25, 5835-5846	4.3	12
112	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. *Current Molecular Medicine*, **2016**, 16, 721-737	2.5	12

111	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. *Liver International*, **2016**, 36, 198-204	7.9	12
110	Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease. *Current Pharmaceutical Design*, **2013**, 19, 5193-5218	3.3	11
109	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. *Frontiers in Pharmacology*, **2019**, 10, 604	5.6	10
108	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. *Journal of Viral Hepatitis*, **2013**, 20, 174-82	3.4	10
107	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 878-884.e1	6.9	10
106	Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. *Hepatitis Monthly*, **2013**, 13, e7176	1.8	10
105	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. *Liver International*, **2021**, 41, 321-332	7.9	10
104	Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?. *Current Pharmaceutical Design*, **2013**, 19, 5297-313	3.3	10
103	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. *Clinical Infectious Diseases*, **2020**, 71, e694-e701	11.6	9
102	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. *Journal of Hepatology*, **2017**,	13.4	9
101	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). *Digestive and Liver Disease*, **2014**, 46, 18-24	3.3	9
100	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. *Digestive Diseases*, **2015**, 33, 668-74	3.2	9
99	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. *Digestive and Liver Disease*, **2012**, 44, 245-50	3.3	9
98	Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. *BMC Infectious Diseases*, **2012**, 12 Suppl 2, S3	4	9
97	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. *Journal of Gastrointestinal and Liver Diseases*, **2020**, 29, 235-245	1.4	9
96	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. *Liver International*, **2020**, 40, 2820-2827	7.9	9
95	Extrahepatic Manifestations of Chronic Viral C Hepatitis. *Gastroenterology Clinics of North America*, **2020**, 49, 347-360	4.4	8
94	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. *Genes and Immunity*, **2016**, 17, 328-34	4.4	8

93	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. *Journal of Viral Hepatitis*, **2012**, 19, 465-72	3.4	8
92	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. *Pathobiology*, **2015**, 82, 48-52	3.6	8
91	Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. *Antiviral Therapy*, **2012**, 17, 111-8	1.6	8
90	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. *Liver International*, **2011**, 31 Suppl 1, 36-44	7.9	8
89	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 517-519	6.9	8
88	A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 564-573	6.1	8
87	Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. *Frontiers in Bioscience - Elite*, **2012**, 4, 1276-86	1.6	7
86	Outcomes of Liver Transplant for Adults With Wilson's Disease. *Liver Transplantation*, **2020**, 26, 507-516	4.5	7
85	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. *Clinical Infectious Diseases*, **2020**, 71, 2810-2817	11.6	7
84	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. *Digestive and Liver Disease*, **2021**, 53, 677-681	3.3	7
83	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. *Infection*, **2018**, 46, 607-615	5.8	7
82	Reply: To PMID 25251399. *Hepatology*, **2015**, 62, 660	11.2	6
81	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. *HIV Medicine*, **2020**, 21, 96-108	2.7	6
80	Ultra-processed food is associated with features of metabolic syndrome and non-alcoholic fatty liver disease. *Liver International*, **2021**, 41, 2635-2645	7.9	6
79	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 777-787.e17	6.9	6
78	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. *Advanced Science*, **2021**, 8, 2004168	13.6	5
77	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. *Ultrasonography*, **2021**, 40, 407-416	4.3	5
76	Expert opinion on managing chronic HCV in patients with cardiovascular disease. *Antiviral Therapy*, **2018**, 23, 35-46	1.6	5

75	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. *Antiviral Therapy*, **2009**, 14, 631-9	1.6	5
74	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 1014-1022	4.5	4
73	Evidence-Based Medicine and the Problem of Healthy Volunteers. *Annals of Hepatology*, **2017**, 16, 832-834	3.1	4
72	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. *Liver Cancer*, **2022**, 11, 75-84	9.1	4
71	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. *JHEP Reports*, **2022**, 4, 100409	10.3	4
70	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158765	5	4
69	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. *Liver International*, **2021**, 41, 2228-2232	7.9	4
68	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1979-1981	6.9	4
67	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). *Digestive and Liver Disease*, **2017**, 49, e60	3.3	3
66	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study). *Liver International*, **2019**, 39, 2240-2243	7.9	3
65	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. *Digestive and Liver Disease*, **2019**, 51, e26	3.3	3
64	Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". *Journal of Hepatology*, **2013**, 58, 403-4	13.4	3
63	Epicardial fat in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2015**, 62, 1215	13.4	3
62	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. *Polish Archives of Internal Medicine*, **2020**, 130, 975-985	1.9	3
61	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. *Current Pharmaceutical Design*, **2020**, 26, 1110-1118	3.3	3
60	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 2103-2110	4.5	3
59	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. *Journal of Hepatology*, **2020**, 73, S13-S14	13.4	3
58	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. *Journal of Viral Hepatitis*, **2021**, 28, 1190-1199	3.4	3

57	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 2389-2396	4	3
56	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Journal of Nephrology*, **2018**, 31, 685-712	4.8	3
55	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. *Liver International*, **2021**, 41, 2712-2719	7.9	3
54	Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. *Current Pharmaceutical Design*, **2013**, 19, 5193-218	3.3	3
53	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). *Digestive and Liver Disease*, **2017**, 49, e59	3.3	2
52	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. *Digestive and Liver Disease*, **2016**, 48, e7-e8	3.3	2
51	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.. *Alimentary Pharmacology and Therapeutics*, **2022**,	6.1	2
50	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. *Current Pharmaceutical Design*, **2020**, 26, 3928-3938	3.3	2
49	Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. *World Journal of Gastroenterology*, **2014**, 20, 16726-33	5.6	2
48	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. *Digestive and Liver Disease*, **2020**, 52, 359-367	3.3	2
47	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). *Digestive and Liver Disease*, **2021**, 53, 1301-1307	3.3	2
46	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). *Digestive and Liver Disease*, **2021**, 53 Suppl 2, S49-S86	3.3	2
45	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Internal and Emergency Medicine*, **2018**, 13, 1139-1166	3.7	2
44	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Digestive and Liver Disease*, **2018**, 50, 1133-1152	3.3	2
43	Is there an 'ideal' diet for patients with NAFLD?. *European Journal of Clinical Investigation*, **2021**, e13659	4.6	2
42	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. *JHEP Reports*, **2022**, 4, 100477	10.3	2
41	Reply: To PMID 24691835. *Hepatology*, **2015**, 61, 1097	11.2	1
40	Genetic variants in the MTHFR are not associated with fatty liver disease. *Liver International*, **2020**, 40, 1934-1940	7.9	1

39	Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'. *Journal of Hepatology*, **2016**, 64, 984-5	13.4	1
38	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". *Journal of Hepatology*, **2014**, 60, 677-8	13.4	1
37	Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?. *Hepatology*, **2012**, 55, 1309; author reply 1309-10	11.2	1
36	PSD3 downregulation confers protection against fatty liver disease.. *Nature Metabolism*, **2022**, 4, 60-75	14.6	1
35	Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.. *Nutrition, Metabolism and Cardiovascular Diseases*, **2022**,	4.5	1
34	Biochemical Biomarkers of NAFLD/NASH **2020**, 89-114		1
33	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. *Liver International*, **2020**, 40, 530-538	7.9	1
32	Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. *World Journal of Gastroenterology*, **2021**, 27, 5112-5125	5.6	1
31	Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors' reply. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 490-490	6.1	0
30	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators.. *JHEP Reports*, **2022**, 4, 100444	10.3	0
29	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). *Canadian Liver Journal*, **2022**, 5, 61-90	0.3	0
28	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. *PLoS ONE*, **2020**, 15, e0243590	3.7	0
27	P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype. *Journal of Crohn's and Colitis*, **2020**, 14, S219-S220	1.5	0
26	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment.. *Clinics and Research in Hepatology and Gastroenterology*, **2022**, 101925	2.4	0
25	Reply. *Hepatology*, **2017**, 65, 2128	11.2	
24	Response to Dr. Sertoglu and colleagues. *Liver International*, **2015**, 35, 285-6	7.9	
23	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance. *Journal of Hepatology*, **2020**, 73, S625-S626	13.4	
22	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. *Digestive and Liver Disease*, **2018**, 50, 58	3.3	

21	Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. *Gut*, **2018**, 67, 403-404	19.2
20	Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?". *Journal of Hepatology*, **2014**, 61, 173-5	13.4
19	Reply: To PMID 22135089. *Hepatology*, **2013**, 57, 422	11.2
18	Is liver stiffness measurement unreliable in obese patients? authors reply. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 255-256	6.1
17	Hyperuricemia in non-alcoholic fatty liver disease: authors reply. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 1043-1044	6.1
16	Reply:. *Hepatology*, **2009**, 49, 1394-1395	11.2
15	Reply:. *Hepatology*, **2009**, 49, 1776-1776	11.2
14	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. *Hepatology*, **2010**, 51, 1858-1858	11.2
13	Reply:. *Hepatology*, **2010**, 51, 2230-2230	11.2
12	Serum BLyS/BAFF levels in acute hepatitis C predict clinical outcome. *Digestive and Liver Disease*, **2008**, 40, A1-A2	3.3
11	Reply:. *Hepatology*, **2008**, 48, 1725-1726	11.2
10	P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression. *Journal of Crohn's and Colitis*, **2022**, 16, i236-i236	1.5
9	Non-invasive Diagnostic Approach to NASH: Biological Markers **2020**, 235-256	
8	Chemoprevention for hepatocellular carcinoma: the role of statins. *Hepatobiliary Surgery and Nutrition*, **2013**, 2, 1-3	2.1
7	Genotype 1 Relapsers and Non-Responders84-89	
6	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. *Digestive and Liver Disease*, **2021**, 53, 1603-1609	3.3
5	Reply. *Hepatology*, **2016**, 63, 1394	11.2
4	Reply. *Hepatology*, **2016**, 64, 701	11.2

3	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). *Infection*, **2019**, 47, 141-168	5.8
2	The Role of Transient Elastography in NAFLD **2021**, 61-74	
1	Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". *Journal of Hepatology*, **2018**, 69, 1203-1204	13.4